Blood Can Miss What Tissue Sees: What a ctDNA Liquid Biopsy Does and Does Not Tell You

Start with what the test is actually looking at. When tumor cells die or turn over, they release fragments of their DNA into the bloodstream. Those fragments are circulating tumor DNA, or ctDNA, and they carry the tumor's own mutations. ctDNA is a small subset of all the cell-free DNA floating in your plasma, most of which comes from healthy cells, and a lab has to pick the tumor signal out of that background (per NCI).

What a liquid biopsy is actually reading

A liquid biopsy is a blood draw analyzed for those tumor fragments. Because ctDNA has a short half-life, roughly 16 minutes to a couple of hours before it clears, the result is close to a real-time snapshot of what the tumor is shedding right now, not a record of last month (per NCBI). That is what makes it powerful for tracking change over time, and also what makes a single draw a thin slice of the whole story.

The signal can be vanishingly small. In some cancers, ctDNA makes up less than 0.1 percent of the cell-free DNA in the sample, below what standard sequencing can reliably see. The most sensitive assays push their limit of detection down toward 0.001 percent, but sensitivity is a hard floor set by biology, not just by the lab (per NCBI). Hold that number in mind, because it is the whole reason a negative result needs a second thought.

What the test is genuinely good at

Used for what it does well, ctDNA is excellent. Three jobs stand out.

It finds targetable mutations. A liquid biopsy can read the same driver mutations a tumor carries and match them to a drug, which is why the FDA has approved tests like Guardant360 Liquid CDx and FoundationOne Liquid CDx as companion diagnostics in non-small cell lung cancer, breast cancer with ESR1 mutations, prostate cancer, and colorectal cancer (per NCI). When a tumor is hard to biopsy, blood can open the door to a targeted therapy that tissue could not reach in time. This overlaps with what a tissue panel decides, covered in tumor genomic testing explained.

It monitors treatment. Because the signal tracks tumor burden, a falling ctDNA level often means a therapy is working, and clearance points to a better outcome (per NCBI). It reads dynamically in a way a one-time scan cannot.

It catches recurrence early. Serial ctDNA testing for minimal residual disease, the tiny amount of cancer left after treatment, can flag a comeback before it is visible on a scan. Systematic reviews have found ctDNA signaling recurrence months ahead of imaging, around 5 months on average across resectable cancers and up to roughly 8 to 9 months in colorectal series (per NCBI). That lead time is the point of MRD monitoring, and it depends on watching the trend across draws, not on any single number. It is a different question from a static blood cancer signal, the kind covered in how to read tumor markers.

Why a clean result is not an all-clear

Here is the trap. A negative ctDNA result does not mean the cancer is gone. It means the test did not see tumor DNA in that tube of blood, which is not the same thing.

The main reason is shedding. Some tumors release very little DNA into the blood, whether because of their size, their location, their blood supply, or their tissue type. Thyroid, kidney, prostate, and brain cancers are known low shedders, and a tumor walled off from the circulation, like an isolated brain metastasis, can be real and active while the blood reads clean (per ASCO). Low tumor burden does the same thing: less cancer means less signal, sometimes below the assay's floor.

That is why the FDA labels for approved liquid biopsies recommend confirming a negative result with tissue testing rather than acting on it as final (per AACR). A negative is best read as "we did not see it, and the test may not be sensitive enough to," never as "it is not there."

When the blood says something that is not cancer

The reverse error exists too. Plasma carries mutations that did not come from a tumor at all. As people age, blood-forming cells acquire their own mutations, a phenomenon called clonal hematopoiesis, and those variants show up in cell-free DNA and can be mistaken for a tumor signal (per NCBI). This is one reason a raw "mutation found" result is not automatically a cancer result, and why tumor-informed assays, which anchor on the mutations your specific tumor is already known to carry, are used to separate true tumor signal from the noise of ordinary aging blood.

The takeaway across both errors is the same. A ctDNA result is a probability statement, not a verdict, and it only means something next to the rest of your picture: the scan, the pathology, the prior draws, the shedding behavior of your particular cancer.

How Healz reads a ctDNA result in the context of your whole case

This is exactly where one result in isolation fails people, and where everything sitting in one chat, not scattered across ten apps and portals, changes the read. Healz is equipped with memory that holds every ctDNA result you upload and connects the trend across serial draws, so a lone "negative" is weighed against your imaging, your pathology, and your earlier numbers instead of being taken at face value. Frontier AI works your case, so a low-shedding tumor type or a borderline drop is flagged rather than waved through. Its root-cause technology does not stop at the first clean tube: it asks whether the test could even see this cancer, cross-checks your case against more than a million rare cases, and pushes toward tissue confirmation when the biology says a negative cannot be trusted. That is the difference between an AI lab report reader that transcribes a number and one that reads cancer signals as a connected story, the kind of second opinion an ai oncologist should give. And when you want a human in the loop, you can bring a board-certified doctor into the same chat for a second opinion.